At ESMO’18, Pfizer Presents Results of PALOMA-3 Trial Results of Ibrance and Fulvestrant

 At ESMO’18, Pfizer Presents Results of PALOMA-3 Trial Results of Ibrance and Fulvestrant

At ESMO’18, Pfizer Presents Results of PALOMA-3 Trial Results of Ibrance and Fulvestrant

Shots:

  • The PALOMA-3 Trial involves assessing of Ibrance (palbociclib) + fulvestrant vs PBO + fulvestrant in women having HR+, HER2- metastatic breast cancer for 2L
  • PALOMA-3 Trial results: mOS (34.9 vs 28.0 mos); mPFS (11.2 vs 4.6 mos); median CT (17.6 vs 8.8 mos.)
  • Ibrance PO is CDKs 4 and 6 inhibitor indicated for HR+, HER2- advance or mBC and has been prescribed to 160,000 patients with approval in 85 countries worldwide

Click here to read full press release/ article | Ref: Pfizer | Image: Mgcop

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post